Dr. Garon on Immunotherapy for Patients With NSCLC

Edward B. Garon, MD
Published: Thursday, Aug 04, 2016


Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non–small cell lung cancer (NSCLC).

The addition of immunotherapy agents to the treatment landscape of NSCLC has led to a very exciting time for a disease originally not believed to be immunogenic, Garon explains.

Today, evidence suggests that such agents could become the frontline choice for select patients with stage IV disease versus standard chemotherapy. 

<<< View more from the 2016 International Lung Cancer Congress


Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non–small cell lung cancer (NSCLC).

The addition of immunotherapy agents to the treatment landscape of NSCLC has led to a very exciting time for a disease originally not believed to be immunogenic, Garon explains.

Today, evidence suggests that such agents could become the frontline choice for select patients with stage IV disease versus standard chemotherapy. 

<<< View more from the 2016 International Lung Cancer Congress


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x